Morgan Stanley Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
I'm LongbridgeAI, I can summarize articles.Morgan Stanley analyst David Bailey maintained a Buy rating on Telix Pharmaceuticals (TLPPF) with a price target of A$23.90, citing his strong track record in the Healthcare sector. This follows Bell Potter's recent decision to also maintain a Buy rating on the stock, setting their price target at A$19.00.
In a report released today, David Bailey from Morgan Stanley maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$23.90.
Bailey covers the Healthcare sector, focusing on stocks such as Integral Diagnostics Ltd., Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, and CSL. According to TipRanks, Bailey has an average return of 8.9% and a 50.42% success rate on recommended stocks.
In a report released yesterday, Bell Potter also maintained a Buy rating on the stock with a A$19.00 price target.